Journal
DNA AND CELL BIOLOGY
Volume 31, Issue -, Pages S49-S61Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/dna.2012.1654
Keywords
-
Funding
- V Scholar Award
- Breast Cancer Alliance Young Investigator Grant
- Melanoma Research Foundation Career Development Award
- Alexander and Margaret Stewart Trust Fellowship
- CTSA Scholar Award from Yale Center for Clinical Investigation
- NIH [CA16359]
- CTSA Grant from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 RR024139]
- NIH roadmap for Medical Research
Ask authors/readers for more resources
Cancer is a collection of very complex diseases that share many traits while differing in many ways as well. This makes a universal cure difficult to attain, and it highlights the importance of understanding each type of cancer at a molecular level. Although many strides have been made in identifying the genetic causes for some cancers, we now understand that simple changes in the primary DNA sequence cannot explain the many steps that are necessary to turn a normal cell into a rouge cancer cell. In recent years, some research has shifted to focusing on detailing epigenetic contributions to the development and progression of cancer. These changes occur apart from primary genomic sequences and include DNA methylation, histone modifications, and miRNA expression. Since these epigenetic modifications are reversible, drugs targeting epigenetic changes are becoming more common in clinical settings. Daily discoveries elucidating these complex epigenetic processes are leading to advances in the field of cancer research. These advances, however, come at a rapid and often overwhelming pace. This review specifically summarizes the main epigenetic mechanisms currently documented in solid tumors common in the United States and Europe.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available